Document Detail


Hydroxyurea therapy in sickle cell anemia patients in Curaçao, The Netherlands Antilles.
MedLine Citation:
PMID:  9352741     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
We have treated 9 patients with sickle cell anemia (SS) with hydroxyurea (HU). All 9 patients carried 4 alpha-globin genes and the beta s-globin haplotypes 19/19 (Benin/Benin), except for 1 who had haplotype 19 together with type 3 (Benin/Senegal). Six patients received HU for 10 months and were again treated with the drug for 5 months after an interval of 1 year. One patient was given HU for 22 consecutive months. A record was kept of hematological and biochemical data, Hb F and G gamma levels, as well as possible clinical complications. Our data show that HU generally improves the hematological and biochemical values and the level of Hb F, and reduces painful crises in some patients. However, although the clinical symptoms improved in some patients during HU therapy, the older patients did not observe any changes in their general condition; the same is the case for the patient with haplotype 19/3. One patient also experienced life-threatening liver sequestration during treatment. We conclude that the selection of patients who may benefit from HU therapy needs further evaluation.
Authors:
A W Saleh; H J Velvis; L H Gu; H F Hillen; T H Huisman
Publication Detail:
Type:  Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Acta haematologica     Volume:  98     ISSN:  0001-5792     ISO Abbreviation:  Acta Haematol.     Publication Date:  1997  
Date Detail:
Created Date:  1997-12-05     Completed Date:  1997-12-05     Revised Date:  2007-11-14    
Medline Journal Info:
Nlm Unique ID:  0141053     Medline TA:  Acta Haematol     Country:  SWITZERLAND    
Other Details:
Languages:  eng     Pagination:  125-9     Citation Subset:  IM    
Affiliation:
Department of Internal Medicine, St. Elisabeth Hospital, Curaçao, The Netherlands Antilles.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Anemia, Sickle Cell / drug therapy*
Antisickling Agents / administration & dosage,  adverse effects,  therapeutic use*
Drug Administration Schedule
Female
Fetal Hemoglobin / analysis
Humans
Hydroxyurea / administration & dosage,  adverse effects,  therapeutic use*
Male
Middle Aged
Netherlands
Grant Support
ID/Acronym/Agency:
HLB-05168/HL/NHLBI NIH HHS
Chemical
Reg. No./Substance:
0/Antisickling Agents; 127-07-1/Hydroxyurea; 9034-63-3/Fetal Hemoglobin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Serum levels of G-CSF, IL-3, IL-6 and GM-CSF after a single intraperitoneal dose of rhG-CSF in letha...
Next Document:  Prognostic factors in elderly patients with non-Hodgkin's lymphoma treated with cyclophosphamide, vi...